| HOME >> BIOLOGY >> TECHNOLOGY |
ts.
Net revenues from EPIAO for the first half of 2010 increased by 27.7% to RMB120.0 million (US$17.7 million) from RMB94.0 million (US$13.8 million) for same period in 2009. Net revenues from TPIAO in the first half of 2010 increased by 51.8% to RMB62.1 million (US$9.2 million) from RMB41.0 million (US$6.0 million) for the same period in 2009. In addition, revenue from our export business was RMB6.0 million (US$0.9 million), representing a decrease of 12.7% over the first half of 2009, while revenue from our IV Iron Sucrose supplement was RMB8.6 million (US$1.3 million), representing an increase of 71.6% over the first half of 2009.
Gross profit. Gross profit for the first half of 2010 increased by 33.2% to RMB183.3 million (US$27.0 million) from RMB137.6 million (US$20.1 million) for the same period in 2009. Gross margin decreased by 0.9% to 90.8% for the first half month months of 2010 from 91.7% for the same period in 2009.
Operating income. For the first half ended June 30, 2010, operating income increased by 22.3% to RMB56.1 million (US$8.3 million), compared to RMB45.9 million (US$6.7 million) for the same period in 2009. Operating margin for the first half ended June 30, 2010 was 27.8% as compared to 30.6% for the half months ended June 30, 2010.
Net income. GAAP net income for the first half of 2010 increased by 21.7% to RMB52.2 million (US$7.7 million) compared with RMB42.9 million (US$6.3 million) for the same period in 2009. GAAP net margin for the first half ended June 30, 2010 was 25.8% as compared to 28.6% for the same period in 2009. GAAP net income per ADS on a fully-diluted basis for the first half of 2010 increased to RMB2.37 (US$0.35) from RMB1.99 (US$0.29) for the same period in 2009.
Non-GAAP net income for the first half of 2010 increased by 13.7% to
RMB52.2 million (US$7.7 million) compared with RMB45.9 million (US$6.7 million)
for the same pe
'/>"/>
| SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |